Perspective · 10 Sep 2026
Conference abstractPublished 29 Jun 2017
New protocol for generation of insulin-specific T regulatory cells
University of Belgrade, Serbia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Immunotherapy of autoimmune diseases with CD4+CD25highFoxP3+ T regulatory cells (Tregs) is currently in the stage of clinical trials. Tregs used for human therapy are polyclonal, but studies in animals showed that autoantigen-specific Tregs are more effective in preventing or ameliorating the pathogenesis of autoimmune diseases compared to polyclonal Tregs. Since Tregs are usually defective in individuals with an autoimmune process, the basic idea of our research was to convert insulin-specific T effector cells into insulin-specific Tregs using various in vitro manipulations. In NOD mice that develop T1D spontaneously, the occurrence of insulin-specific CD4+ T cells was 0,1%. In order to increase the number of insulin-specific T cells, CD4+ T cells were co-cultivated in vitro with autologous mature dendritic cells in the presence of insulin peptide (B9:23). The proportion of insulin-specific CD4+ cells after 48 h increased up to 3,4Ã?±0,1% and this level remained stable for 2 days. Insulin-specific CD4+ cells were then stained by fluorescent insulin-loaded MHC class II tetramer and sorted using flow cytometer. Obtained cells were cultured in RPMI-1640 medium supplemented with TCR stimulators (anti-CD3 and anti-CD28 antibody), recombinant IL-2 and TGF-Ã?² proteins. After 5 days, the number of CD4+CD25highFoxP3+ Tregs reached 48%. However, further cultivation (with medium replacement every second day) did not lead to an increase in the number of Tregs, on the contrary, the Treg proportion was reduced to 14%. These results imply that it is feasible to generate antigen-specific Tregs from antigen-specific effector cells, but the protocol still requires a few modifications in order to produce sufficient number of Tregs for in vivo use.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Ivana Stojanovic”
- BylineArticles whose byline prints “Neda Đedovic”
- BylineArticles whose byline prints “Verica Paunovic”
